Roche

Grenzacherstrasse 124, 4070 Basel
Roche   link
Location: Basel
Discipline: Pharmacology
Pharmacology - Health - May 28
Roche is also close to completing enrolment of a global randomised, double-blind, placebo-controlled phase III clinical trial of Actemra /RoActemra (tocilizumab) in hospitalised patients with severe COVID-19 pneumonia (COVACTA), with results expected this summer.
Pharmacology - Health - Jan 27

Application is being reviewed under FDA's Real-Time Oncology Review pilot programme Roche today announced the completion of a supplemental Biologics License Application (sBLA) submission to the US Food and Drug Administration (FDA) for Tecentriq (atezolizumab) in combination with Avastin (bevaciz

Pharmacology - Health - Dec 16, 2019

All antitrust approvals required to close the transaction received. Roche and Spark Therapeutics, Inc.

Pharmacology - Health - Dec 12, 2019

Fixed-dose combination administered under the skin in just minutes, compared to hours with intravenous administration, significantly reducing time spent receiving treatment Phase III FeDeriCa study showed non-inferior pharmacokinetics and comparable efficacy and safety with the fixed-dose combina

Health - Pharmacology - Dec 10, 2019

Accu-Chek SugarView is the first app that determines blood glucose ranges by taking photos with the smartphone camera without the need of a blood glucose meter. It is designed to help non-insulin-dependent people with type 2 diabetes or pre-diabetes live healthier lives in-between doctors' visits.

Pharmacology - Health - Jan 21

Novel combination regimen includes first-in-class antibody-drug conjugate that specifically targets CD79b Targeted off-the-shelf treatment provides much-needed new option for people with relapsed or refractory diffuse large B-cell lymphoma Polivy approval is based on a phase Ib/II study, the firs

Pharmacology - Health - Dec 13, 2019

Roche today announced the Phase III IMspire150 study, in people with previously untreated BRAF V600 mutation-positive advanced melanoma, met its primary endpoint of progression-free survival (PFS).

Pharmacology - Health - Dec 11, 2019

Greatest improvement in invasive disease-free survival (iDFS) remains in patients at high risk of recurrence, such as those with lymph node-positive disease with a 28% reduction in the risk of recurrence or death, corresponding to an absolute iDFS benefit of 4.5% at six years With longer f

Pharmacology - Health - Dec 8, 2019

In an updated analysis of the CLL14 study, Venclexta/Venclyxto plus Gazyva/Gazyvaro achieved remissions that were sustained over time in people with previously untreated chronic lymphocytic leukaemia At four-year follow-up of the MURANO study, Venclexta/Venclyxto plus MabThera/Rituxan continued t





Website Preview

Link

Medicine and Life Sciences